IPHA
Innate Pharma SA Sponsored ADR · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website innate-pharma.com
- Employees(FY) 191
- ISIN US45781K2042
Performance
+4.12%
1W
-2.69%
1M
+1.2%
3M
+2.85%
6M
-9.64%
YTD
-13.8%
1Y
Profile
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH4501, an antibody drug conjugates (ADC); and IPH65, a tetra-specific proprietary antibody. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.
Technical Analysis of IPHA 2024-05-10
Overview:
In analyzing the technical indicators for IPHA over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key aspects, we aim to offer valuable insights and predictions for the upcoming days.
Trend Analysis:
...Recent News & Updates
- 2024-05-06 13:00
- 2024-04-14 13:00
- 2024-04-14 13:00
- 2024-04-10 00:00
- 2024-04-09 13:00
- 2024-04-08 13:00
- 2024-04-04 15:34
- 2024-03-21 23:33
- 2024-03-20 14:00
- 2024-03-18 14:00
- 2024-03-13 14:00
- 2024-03-05 12:00
- 2024-03-05 12:00
- 2024-02-20 12:00
- 2024-01-11 12:00
- 2024-01-03 12:00
- 2024-01-03 11:59
- 2023-12-18 12:00
- 2023-12-17 12:00
Innate Pharma Announces Leadership Change(Businesswire)
- 2023-12-10 12:00
- 2023-12-09 12:00
- 2023-11-26 12:00
Innate Pharma to Host Virtual KOL Event on Lacutamab(Businesswire)
- 2023-11-14 21:36
- 2023-11-13 12:00
- 2023-11-06 12:00
- 2023-11-02 14:00
- 2023-10-26 13:00
- 2023-10-18 13:00
Innate Pharma 2024 Financial Calendar(Businesswire)
- 2023-10-15 13:00
- 2023-10-08 13:00
Page 1 of 4
previousnext